Shopping Cart 0
Cart Subtotal
USD 0

Cancer Pain - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Cancer Pain-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cancer Pain-Pipeline Review, H2 2018, provides an overview of the Cancer Pain (Central Nervous System) pipeline landscape.

Cancer pain can be defined as a complex sensation that reflects both damage to the body and the body's response to the damage. Pain may arise due to tumor compressing or infiltrating tissue, from treatments and diagnostic procedures, or from skin, nerve and other changes caused by either the body's immune response or hormones released by the tumor. Cancer pain can be treated by analgesic drug therapy, non-opioid analgesics, opioid analgesics, adjuvant drugs, psychotherapy, anesthetic and neurosurgical pain management.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cancer Pain-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Cancer Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cancer Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cancer Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 8, 5, 15, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Cancer Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cancer Pain (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Cancer Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Cancer Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Cancer Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Cancer Pain (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Cancer Pain (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Cancer Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 5

Cancer Pain-Overview 6

Cancer Pain-Therapeutics Development 7

Cancer Pain-Therapeutics Assessment 15

Cancer Pain-Companies Involved in Therapeutics Development 24

Cancer Pain-Drug Profiles 38

Cancer Pain-Dormant Projects 101

Cancer Pain-Discontinued Products 105

Cancer Pain-Product Development Milestones 106

Appendix 117


List Of Figure

List of Figures

Number of Products under Development for Cancer Pain, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Top 10 Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Cancer Pain, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Cancer Pain-Pipeline by Alexza Pharmaceuticals Inc, H2 2018

Cancer Pain-Pipeline by AngioChem Inc, H2 2018

Cancer Pain-Pipeline by Aoxing Pharmaceutical Company Inc, H2 2018

Cancer Pain-Pipeline by Aphios Corp, H2 2018

Cancer Pain-Pipeline by AstraZeneca Plc, H2 2018

Cancer Pain-Pipeline by ChironWells GmbH, H2 2018

Cancer Pain-Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018

Cancer Pain-Pipeline by Dompe Farmaceutici SpA, H2 2018

Cancer Pain-Pipeline by Fujimoto Pharmaceutical Corp, H2 2018

Cancer Pain-Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2018

Cancer Pain-Pipeline by Immupharma Plc, H2 2018

Cancer Pain-Pipeline by IntelGenx Corp, H2 2018

Cancer Pain-Pipeline by iX Biopharma Ltd, H2 2018

Cancer Pain-Pipeline by Klaria Pharma Holding AB, H2 2018

Cancer Pain-Pipeline by Komipharm International Co Ltd, H2 2018

Cancer Pain-Pipeline by Medlab Clinical Ltd, H2 2018

Cancer Pain-Pipeline by Nanomerics Ltd, H2 2018

Cancer Pain-Pipeline by Neurocentrx Pharma Ltd, H2 2018

Cancer Pain-Pipeline by Nippon Kayaku Co Ltd, H2 2018

Cancer Pain-Pipeline by Nippon Zoki Pharmaceutical Co Ltd, H2 2018

Cancer Pain-Pipeline by Oblique Therapeutics AB, H2 2018

Cancer Pain-Pipeline by Orion Corp, H2 2018

Cancer Pain-Pipeline by Pain Therapeutics Inc, H2 2018

Cancer Pain-Pipeline by Pfizer Inc, H2 2018

Cancer Pain-Pipeline by Pharmaleads SA, H2 2018

Cancer Pain-Pipeline by Plexxikon Inc, H2 2018

Cancer Pain-Pipeline by Recordati SpA, H2 2018

Cancer Pain-Pipeline by Ribomic Inc, H2 2018

Cancer Pain-Pipeline by Sorrento Therapeutics Inc, H2 2018

Cancer Pain-Pipeline by Tetra Bio-Pharma Inc, H2 2018

Cancer Pain-Pipeline by Virobay Inc, H2 2018

Cancer Pain-Pipeline by WEX Pharmaceuticals Inc, H2 2018

Cancer Pain-Dormant Projects, H2 2018

Cancer Pain-Dormant Projects, H2 2018 (Contd..1), H2 2018

Cancer Pain-Dormant Projects, H2 2018 (Contd..2), H2 2018

Cancer Pain-Dormant Projects, H2 2018 (Contd..3), H2 2018

Cancer Pain-Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Cancer Pain Therapeutic Products under Development, Key Players in Cancer Pain Therapeutics, Cancer Pain Pipeline Overview, Cancer Pain Pipeline, Cancer Pain Pipeline Assessment


Companies

Alexza Pharmaceuticals Inc

AngioChem Inc

Aoxing Pharmaceutical Company Inc

Aphios Corp

AstraZeneca Plc

ChironWells GmbH

Daewoong Pharmaceutical Co Ltd

Dompe Farmaceutici SpA

Fujimoto Pharmaceutical Corp

Hisamitsu Pharmaceutical Co Inc

Immupharma Plc

IntelGenx Corp

iX Biopharma Ltd

Klaria Pharma Holding AB

Komipharm International Co Ltd

Medlab Clinical Ltd

Nanomerics Ltd

Neurocentrx Pharma Ltd

Nippon Kayaku Co Ltd

Nippon Zoki Pharmaceutical Co Ltd

Oblique Therapeutics AB

Orion Corp

Pain Therapeutics Inc

Pfizer Inc

Pharmaleads SA

Plexxikon Inc

Recordati SpA

Ribomic Inc

Sorrento Therapeutics Inc

Tetra Bio-Pharma Inc

Virobay Inc

WEX Pharmaceuticals Inc